The data reviewed by the FDA and CDC included clinical trial results looking at a slightly different COVID-19 bivalent booster: one that included the original coronavirus strain and BA.1, which like BA.4 and BA.5, is a subvariant of omicron. Mouse studies looking at the safety and effectiveness of the BA.4/5 bivalent vaccine were also considered; clinical trial results in humans are forthcoming.